Mark Higgins

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation

K. De Boeck, À. Munck, Seth Walker et al. · Journal of Cystic Fibrosis · 2014 · 379 citations · Full text

Medicine, Non-g551d Gating Mutation, Pathology

Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease

James F. Donohue, Charles Fogarty, Jan Lötvall et al. · American Journal of Respiratory and Critical Care Medicine · 2010 · 346 citations

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

Michael W. Konstan, Patrick A. Flume, Matthias Kappler et al. · Journal of Cystic Fibrosis · 2010 · 310 citations · Full text

Eager Trial, Antibiotics, Cystic Fibrosis Patients +3

Efficacy of a new once-daily long-acting inhaled  2-agonist indacaterol versus twice-daily formoterol in COPD

Ronald Dahl, Kian Fan Chung, Roland Buhl et al. · Thorax · 2010 · 272 citations · Full text

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Margaret Rosenfeld, Claire Wainwright, Mark Higgins et al. · The Lancet Respiratory Medicine · 2018 · 262 citations · Full text

Medicine, Cftr Gating Mutation, Pediatrics +1